Sacituzumab Govitecan (IMMU-132) in treatment-resistant uterine serous carcinoma: A case report

Chanhee Han, Stefania Bellone, Peter E Schwartz, Serengulam V Govindan, Robert M Sharkey, David M Goldenberg, Alessandro D Santin, Chanhee Han, Stefania Bellone, Peter E Schwartz, Serengulam V Govindan, Robert M Sharkey, David M Goldenberg, Alessandro D Santin

Abstract

Background: Uterine serous carcinoma (USC) is a biologically aggressive variant of uterine cancer. Effective treatment options for recurrent, chemotherapy-resistant USC are extremely limited.

Case: We describe a 74-year-old woman with recurrent and widespread treatment-resistant disease, who experienced a dramatic response to sacituzumab govitecan, a novel antibody-drug conjugate (ADC) targeting human trophoblast-cell-surface antigen (TROP-2), after failing multiple chemotherapy and immunotherapy. The impressive clinical response (66% reduction of target lesions by RECIST 1.1 with a duration response of over 10 months) was confirmed with serial CT scans in the absence of significant adverse events.

Conclusion: Sacituzumab govitecan may present a new treatment option for recurrent USC patients harboring Trop-2+ tumors resistant to chemotherapy. Clinical trials with sacituzumab govitecan are warranted.

Keywords: IMMU-132; Recurrent; Sacituzumab govitecan; Treatment-resistant; Uterine serous carcinoma.

Figures

Fig. 1
Fig. 1
Representative microscopic image of recurrent uterine serous carcinoma. Immunohistochemistry demonstrates strong Trop-2 staining. ×100 magnification.
Fig. 2
Fig. 2
Representative CT scans demonstrating activity of IMMU-132.
  1. A.

    Pretreatment images with baseline measurements of the target lesion (arrow) of the liver.

  2. B.

    Regression of the liver lesion (arrow) after 4 cycles of IMMU-132: partial response with 35% size reduction in target lesions by RECIST 1.1.

  3. C.

    Regression of the liver lesion (arrow) after 6 months of IMMU-132: partial response with 51% size reduction in target lesions by RECIST 1.1.

  4. D.

    Regression of the liver lesion (arrow) after 10 months of IMMU-132: partial response with 65.7% size reduction in target lesions by RECIST 1.1.

Fig. 3
Fig. 3
Timeline of patient's disease course with treatment: (C/T, carboplatin/paclitaxel; PD, progression of disease; ddT, dose dense paclitaxel; NED, no evidence of disease; PR, partial response).

References

    1. Bardia A., Mayer I.A., Diamond J.R., Moroose R.L., Isakoff S.J., Starodub A.N. Efficacy and safety of anti-Trop-2 antibody drug conjugate sacituzumab govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative breast cancer. J. Clin. Oncol. 2017;35(19):2141–2148.
    1. Bignotti E., Ravaggi A., Romani C., Falchetti M., Lonardi S., Facchetti F. Trop-2 overexpression in poorly differentiated endometrial endometrioid carcinoma: implications for immunotherapy with hRS7, a humanized anti-trop-2 monoclonal antibody. Int. J. Gynecol. Cancer. 2011;21(9):1613–1621.
    1. Bignotti E., Zanotti L., Calza S., Falchetti M., Lonardi S., Ravaggi A. Trop-2 protein overexpression is an independent marker for predicting disease recurrence in endometrioid endometrial carcinoma. BMC Clin. Pathol. 2012;12:22.
    1. Boruta D.M., 2nd, Gehrig P.A., Fader A.N., Olawaiye A.B. Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) review. Gynecol. Oncol. 2009;115(1):142–153.
    1. Cardillo T.M., Govindan S.V., Sharkey R.M., Trisal P., Arrojo R., Liu D. Sacituzumab govitecan (IMMU-132), an anti-Trop-2/SN-38 antibody-drug conjugate: characterization and efficacy in pancreatic, gastric, and other cancers. Bioconjug. Chem. 2015;26(5):919–931.
    1. Cirisano F.D., Jr., Robboy S.J., Dodge R.K., Bentley R.C., Krigman H.R., Synan I.S. Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma. Gynecol. Oncol. 1999;74(3):385–394.
    1. Conroy T., Desseigne F., Ychou M., Bouche O., Guimbaud R., Becouarn Y. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 2011;364(19):1817–1825.
    1. Faltas B., Goldenberg D.M., Ocean A.J., Govindan S.V., Wilhelm F., Sharkey R.M. Sacituzumab govitecan, a novel antibody—drug conjugate, in patients with metastatic platinum-resistant urothelial carcinoma. Clin. Genitourin. Cancer. 2016;14(1):e75–e79.
    1. Goldenberg D.M., Cardillo T.M., Govindan S.V., Rossi E.A., Sharkey R.M. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC) Oncotarget. 2015;6(26):22496–22512.
    1. Gray J.E., Heist R.S., Starodub A.N., Camidge D.R., Kio E.A., Masters G.A. Therapy of small cell lung Cancer (SCLC) with a topoisomerase-I-inhibiting antibody-drug conjugate (ADC) targeting Trop-2, sacituzumab govitecan. Clin. Cancer Res. 2017;23(19):5711–5719.
    1. Heist R.S., Guarino M.J., Masters G., Purcell W.T., Starodub A.N., Horn L. Therapy of advanced non-small-cell lung Cancer with an SN-38-anti-Trop-2 drug conjugate, sacituzumab govitecan. J. Clin. Oncol. 2017;35(24):2790–2797.
    1. Starodub A.N., Ocean A.J., Shah M.A., Guarino M.J., Picozzi V.J., Jr., Vahdat L.T. First-in-human trial of a novel anti-Trop-2 antibody-SN-38 conjugate, sacituzumab govitecan, for the treatment of diverse metastatic solid tumors. Clin. Cancer Res. 2015;21(17):3870–3878.
    1. Varughese J., Cocco E., Bellone S., de Leon M., Bellone M., Todeschini P. Uterine serous papillary carcinomas overexpress human trophoblast-cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized anti-Trop-2 monoclonal antibody. Cancer. 2011;117(14):3163–3172.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe